Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 128,180

Document Document Title
WO/2024/110932A1
of the Disclosure The invention relates to a Fibroblast Growth Factor 2 (FGF-2) polypeptides that have improved stability while maintaining biological activity compared to the wild-type of FGF-2. The invention provides the process for th...  
WO/2024/112809A2
Disclosed are peptides and conjugates of the peptide covalently bonded or linked via a linker to a therapeutic or diagnostic molecule, the peptide including at least one cationic domain and at least one hydrophobic domain.  
WO/2024/112814A1
The present invention provides novel fusion proteins comprising two cytokines: interleukin-6 (IL-6) and interleukin-1 beta (IL-1β). Methods of using the fusion proteins to activate target cells or treat a disease are also provided.  
WO/2024/109169A1
Described in the present application are a series of mature polypeptide sequences. The amino acid sequences of the mature polypeptide sequences are obtained by means of performing modification at at least one of positions 233, 271, 312, ...  
WO/2024/110539A1
The present invention discloses the application of Duckweed Pericarp Color1 (P1) protein homologues (P1-Ls) such as LtP1-L or LeP1-L in regulating the biosynthesis of orientin and/or isoorientin in duckweed or other plants. Specifically,...  
WO/2024/110763A1
A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative...  
WO/2024/108312A1
The present invention relates to compositions, methods and uses of Teneurin C-Terminal Associated Peptide (TCAP) as an antagonist of corticotropin-releasing factor (CRF). In some other embodiments the invention relates to methods and use...  
WO/2024/110675A1
The present invention relates to a method of obtaining an exclusively physical concentrated extract of the miraculin protein (MIR). The method is essentially based on membrane ultrafiltration to concentrate the protein without affecting ...  
WO/2024/110878A1
Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs that can be vectorized for vector-mediated therapy, for example, viral-vector media...  
WO/2024/109611A1
Provided is a mutant respiratory syncytial virus pre-fusion F protein, having the following mutations compared with a wild-type respiratory syncytial virus pre-fusion F protein: (a) at least one amino acid residue in an F1 subunit and/or...  
WO/2024/112118A1
The present invention relates to stem cells transfected with a vector into which MyoG, MyoD, and Myf6, which are genes for enhancing muscle differentiation, are co-introduced, and a preparation method therefor. When using the present inv...  
WO/2024/108657A1
Provided are a photosensitive nuclear recessive male sterility gene Ghpsm5 and an application thereof in cotton, which relate to the technical field of genetic engineering and agricultural crop genetic breeding. Provided is a photosensit...  
WO/2024/108530A1
The present invention provides a polypeptide antagonist targeting a Pannexin 1 channel protein. The polypeptide of the present invention comprises a polypeptide fragment consisting of 10-22 consecutive amino acids of an amino acid sequen...  
WO/2024/112581A1
Some embodiments provided herein include methods and compositions comprising chimeric antigen receptors (CARs) which specifically bind biotin conjugated to a molecule (conjugated biotin). Some embodiments include therapies for inhibiting...  
WO/2024/108780A1
A method for extracting and purifying phycocyanin from Spirulina platensis. Dried Spirulina platensis cells with polysaccharide enriched on the surface are obtained by means of spray drying with salt; by means of a salt solvent, the exud...  
WO/2024/110070A1
The present invention relates to a spinach plant that is resistant to downy mildew caused by Peronospora farinosa. The present invention further relates to a resistance gene that confers resistance to downy mildew in spinach plants and m...  
WO/2024/112776A1
Methods of treating various types of cancer, including breast cancer, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C Motif Chemokine Receptor 4 immunotoxin...  
WO/2024/108862A1
Provided are a rice white leaf and panicle gene wlp3, a cDNA sequence thereof being as shown in SEQ ID NO. 1, and a coding amino acid sequence being as shown in SEQ ID NO. 2. The rice white leaf and panicle gene wlp3 is applied to improv...  
WO/2024/109339A1
Provided is use of a Caerin1.1/1.9 combined with an anti-CD47 antibody in the preparation of a drug for the treatment of melanoma. An amino acid sequence of Caerin1.1 is as set forth in SEQ ID NO. 1. An amino acid sequence of Caerin1.9 i...  
WO/2024/110397A1
The invention relates in general to the field of CAR-T cells. The invention in particular relates to improved methods for obtaining CAR-T cells, and improved CAR-T cells, as well as uses thereof. The method in further relates to activati...  
WO/2024/110757A1
The invention provides constructs, pharmaceutical compositions, methods of preparing a ferritin nanocage, ferritin nanocages, methods of treating or preventing a disease in a subject, and methods of raising an immune response against an ...  
WO/2024/112773A1
Described herein are DNA editing constructs including a DNA editing motif, a nuclear localization signal, and a single stranded DNA binding motif. The DNA editing constructs, when used together with a single stranded DNA donor template, ...  
WO/2024/110751A1
The present invention provides a constitutively active recombinant receptor that activates STAT signalling, wherein the recombinant receptor comprises an exodomain that is not derived from the extracellular region of EPOR; a transmembran...  
WO/2024/108303A1
Lymphoid leukemia such as acute lymphoblastic leukemia (ALL) represents a devastating disease especially when it occurs in adults. While dose-intensification strategies have led to a significant improvement in outcomes for pediatric pati...  
WO/2024/108304A1
Metal-protein conjugates for use in mass cytometry and methods of making the same are provided. The metal-protein conjugates may have a metal directly bound to the protein, or have a metal attached to the protein through a linking moiety...  
WO/2024/112821A1
The present disclosure relates to expression of fusion proteins for cancer immunotherapy in a mammalian subject, such as a human subject. In particular, the present disclosure relates to mRNA, self-replicating RNA, and temperature-sensit...  
WO/2024/107745A1
Provided herein are methods and compositions for detecting and measuring MTBR-tau species in CSF, and uses thereof for detecting pathological features and/or clinical symptoms of tauopathies, which may be used to diagnose, stage, or choo...  
WO/2024/103167A1
A multi-valent vaccine is provided which targets the multi-stage life cycle of Mycobacterium species of the tuberculosis complex. The vaccine comprises a transgene that expresses an acute mycobacterial infection-associated antigen such a...  
WO/2024/103860A1
Provided is a site-specific PEG-modified interleukin 2 (IL-2) mutant. Compared with a parent IL-2, the mutant has an improved preference for a Treg cell and a prolonged half-life period. Also provided are a composition comprising the IL-...  
WO/2024/108001A2
Described herein are virus-like particles (VLPs) and minimal human-derived virus-like particles (mhVLPs), comprising a membrane comprising a phospholipid bilayer with one or more human-derived envelope glycoproteins (env) on the external...  
WO/2024/106941A1
The present invention relates to: an expression cassette comprising a polynucleotide that encodes a chimeric antigen receptor effective in cancer treatment; and an effector cell into which the expression cassette is transduced. Particula...  
WO/2024/107038A1
The present invention relates to a method for manufacturing ethyl phenylalanine amido collagen (EPC) and a delivery formulation containing same. A delivery agent can be obtained economically and efficiently using the method for manufactu...  
WO/2024/106866A1
The present invention relates to a DNA construct including: a gene encoding a flagellin protein; and a gene encoding an immunoenhancer (adjuvant) protein. For effective cancer therapy by selectively killing only cancer cells, an attenuat...  
WO/2024/104947A2
Provided herein are isolated mutant influenza hemagglutinin polypeptides, methods for providing isolated mutant influenza hemagglutinin polypeptides, methods of use of the isolated mutant influenza hemagglutinin polypetides as a diagnost...  
WO/2024/103504A1
The present application relates to a marker and a method for detecting inflammation-related diseases. The marker of the present application can stably exist in an ex vivo body fluid sample and does not gather on a cell membrane, so the d...  
WO/2023/077038A9
The present disclosure relates to compositions and methods of uses of a monoallelic MHC-expressing cell line, as well as method of identifying a neoepitope-MHC binding pair and methods of treating a subject having a cancer or tumor expre...  
WO/2024/107959A1
Described herein are minimal virus-like particles (mVLPs), comprising a membrane comprising a phospholipid bilayer with one or more ectodomain-truncated VSV envelope glycoproteins on the external side; and a biomolecule cargo disposed in...  
WO/2024/107597A1
Methods and compositions for identifying, selecting and/or producing a pathogen resistant plant, plant cell or seed (e.g., a legume or soybean plant, plant cell or seed) are provided. Polynucleotides and polypeptides are provided, which ...  
WO/2024/105236A1
Provided are non-plant polypeptides or proteins comprising xylosylated N-linked glycans that comprise β1,2-xylose, wherein at least 25% of the individual protein species comprise xylosylated N-glycans, compositions comprising the non-pl...  
WO/2024/106737A1
The present invention relates to use of a substance containing a point-mutation FoxM1 protein and peptide for inhibiting the growth, mobility, and invasiveness of cancer cells. In addition, the present invention relates to a use of the s...  
WO/2024/107983A1
Described herein are programmable tropism virus-like particles (ptVLPs), comprising a membrane comprising a phospholipid bilayer with one or more wild-type or mutant/truncated virus-derived glycoproteins on the external side. The virus-d...  
WO/2024/107670A1
The present disclosure provides chimeric proteins that are designed to target cell-based immunotherapy more specifically to tumors and the tumor microenvironment. Use of membrane-bound effector molecules reduces the off-target side effec...  
WO/2024/108209A1
Compositions and methods for the treatment of obesity and metabolic disorders using an GPR75 inhibitor are provided herein.  
WO/2024/107827A1
In certain aspects, provided herein are mutant stimulator of interferon genes (STING) polypeptides, compositions thereof and methods of using the same, wherein the mutation is within the dimerization interface of the STING, and wherein t...  
WO/2024/104444A1
The present invention provides an IL-2 mutant and a use thereof. The IL-2 mutant comprises an amino acid mutation in position 125 of a protein represented by SEQ ID NO: 1 and an amino acid mutation in at least one of the following sites:...  
WO/2024/104584A1
The technology provided herein relates to novel Pseudomonas exotoxin A enzymes (PEs); to nucleic acid molecules encoding said PEs, vectors, host cells containing the nucleic acids and methods for preparation and producing such PEs; compo...  
WO/2024/107029A1
The present invention relates to a dual gene-transduced T cell using a CTLA-4 variant and a chimeric antigen receptor, and a composition containing same for cancer immunotherapy. According to one aspect, the dual gene-transduced T cell u...  
WO/2024/106355A1
The present invention addresses the problem of providing novel cells for an ex-vivo gene therapy that produce a modified factor VIII. Cells for an ex-vivo gene therapy according to the present invention, as means for solving the problem,...  
WO/2024/107749A1
The present disclosure relates in some aspects to compositions and methods of using variable domain of immunoglobulin new antigen receptor (VNAR)-Fc-peptide fusion proteins that are capable of uptake across the blood-brain barrier (BBB) ...  
WO/2024/104412A1
Provided herein are modified IFNα2b proteins and functional fragments thereof. Also provided are polypeptides, such as bi-functional and multi-functional ones, which further include a biological moiety such as an antibody or antigen-bin...  

Matches 151 - 200 out of 128,180